Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502164 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
A Phase 1 study of Advanced Prostate Adenocarcinoma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00502164 is a Phase 1 study of Advanced Prostate Adenocarcinoma that has completed, run by AstraZeneca. The registered enrollment target is 40 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00502164, a Phase 1 study of Advanced Prostate Adenocarcinoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
Conditions Studied
Interventions
- DRUG AZD2171
Study Locations (3)
California
- Research Site - San Francisco
Illinois
- Research Site - Chicago
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00502164
The ClinicalTrials.gov registry entry for NCT00502164 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which AZD2171 is the first listed.
NCT00502164 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00502164 about?
NCT00502164 is a clinical study titled "Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer". A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
What is the current status of trial NCT00502164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-03.
What conditions does trial NCT00502164 study?
This clinical trial studies the following conditions: Advanced Prostate Adenocarcinoma.
What interventions are being tested in trial NCT00502164?
The interventions under investigation include: AZD2171 (DRUG).
Who is sponsoring clinical trial NCT00502164?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00502164 being conducted?
This trial has 3 study locations across California, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.